Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Poly(ADP-ribose) polymerase (PARP) enzymes are crucial for DNA repair and genomic stability.
• Olaparib, a PARP inhibitor, offers clinical benefits for BRCA-mutated cancers but has limitations in toxicity and pharmacokinetics.
• There is a need for novel PARP inhibitors with improved properties.

Purpose of the Study:

• To characterize the preclinical profile of fluzoparib (SHR-3162), a novel oral PARP inhibitor.
• To evaluate its efficacy, safety, and potential for combination therapies in cancer models.

Main Methods:

• In vitro enzyme inhibition assays for PARP1.
• Assessment of DNA damage, cell cycle arrest, and apoptosis in cancer cells.
• In vivo studies using HR-deficient xenograft models.
• Combination studies with apatinib and paclitaxel.

Main Results:

• Fluzoparib demonstrated potent inhibition of PARP1 activity.
• It induced DNA damage, G2/M arrest, and apoptosis in HR-deficient cells.
• Fluzoparib exhibited superior antitumor activity, good pharmacokinetics, and a favorable toxicity profile in preclinical models.
• Combinations of fluzoparib with apatinib or apatinib plus paclitaxel showed enhanced antitumor responses without increased toxicity.

Conclusions:

• Fluzoparib is a potent, orally available PARP inhibitor with promising preclinical efficacy and safety.
• Fluzoparib demonstrates potential as a therapeutic agent, particularly in combination therapies for cancer treatment.
• Clinical trials are underway to further evaluate fluzoparib's efficacy and safety in cancer patients.